The document discusses developing a new hybrid formulation of aspirin using nanoparticles to improve its solubility, absorption and bioavailability for cancer prevention and treatment. It aims to provide a safe, low-cost option for both reducing cancer risk and supporting patients by reducing pain, inflammation and improving quality of life. The hybrid works by inhibiting Cox-1 and Cox-2 enzymes to reduce prostaglandin production and inflammation, restricting the spread of cancer cells. It has completed proof of concept and early-stage development and requires further animal testing, manufacturing development and clinical trials before approval and commercialization.
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
Aspirin as nanomedicine
1. Not just for pain
But
More……………………………………………..
Aspirin
Hybrid
A new approach for cancer prevention and control
No matter how easy cancer treatment may become, it is preferable to prevent cancer
Dual
Action
Mewa Singh
609-902-7128
mewasinghsandhu@hotmail.com
2. Therapeutic compounds, such as aspirin, are most
stable in a crystalline form, but can display poor
aqueous solubility and slow dissolution rates. These
properties impart the tendency to reduce the
bioavailability of the active pharmaceutical ingredient
(API), thereby slowing absorption.
A
safe solution from Meda Biotech
3.
We believe there isn't one way to beat cancer - there
are hundreds. For nearly 7 years, we've been
committed to finding the right combination for cancer
prevention that is safe and effective and of low cost
At the same time, it should support patient with
therapies to boost immune system, reduce pain and
improve quality of life
Dual
Action
4.
1. A pharmaceutical composition for treatment of
conditions in mammals which are responsive to COX2 inhibition which comprises in combination an
effective amount of a COX-2 inhibitor and low-dose
aspirin, wherein said low-dose of aspirin is equivalent
to less than 75 milligrams per day of aspirin, for
simultaneous, sequential or separate use wherein
said condition is selected from the group of acute
coronary ischemic syndrome, thrombosis,
thromboembolism, thrombic occlusion and
reocclusion, transient ischemic attack, myocardial
infarction and first or subsequent thrombic stroke.
Dual
Action
5. Rational
Acetylsalicylic acid may just keep cancers away, or so suggests a report
released in the U.K. medical journal Lancet on December 7, 2010. The
researchers looked at a great deal of data to come to their conclusion, with
Dr. Peter M. Rothwell and colleagues examining records from 25,570
patients who had taken part in eight trials (“Effect of Daily Aspirin on Longterm Risk of Death Due to Cancer.”)
Can Low-Dose Acetylsalicylic Acid Prevent Cancer? | Suite101.com
http://www.suite101.com/news/more-benefit-from-daily-lowdose-aspirin-cancer-prevention-a317573#ixzz1v8Nw2ldT
Nanosgroup AspirinHybrid is one step ahead of this game plan
Dual
Action
6. Rational
"Aspirin - which deactivates an enzyme associated with
inflammation - offers a plausible means of reducing the
inflammation that is part of cancer progression," he wrote about
study results. "Effects of aspirin were strongest for cancers of the
gastrointestinal tract, where aspirin exerts its most direct effects.
This study reaffirms a potential role for aspirin in both cancer
prevention and treatment, and suggests new directions for anticancer drug development.
Read more at Suite101: Can Low-Dose Acetylsalicylic Acid
Prevent Cancer? | Suite101.com
http://www.suite101.com/news/more-benefit-from-daily-lowdose-aspirin-cancer-prevention-a317573#ixzz1v8QWf1Ix
No matter how easy cancer treatment may become, it is preferable to prevent cancer
Dual
Action
7. Rational
Inflammation is believed to contribute to a
variety of cancers. Long-term inflammation leads
to abnormal cell growth, or dysplasia. Examples
include inflammation from infection. HPV can
lead to cervical cancer and Hepatitis B puts
individuals at risk for liver cancer.
http://digitaljournal.com/article/320418#ixzz1v
8h3lpMY
No matter how easy cancer treatment may become, it is preferable to prevent cancer
Dual
Action
8. Rational
The scientists who developed the new drug decided
including NO and H2S probably had dual benefits, so they
came up with the „NOSH aspirin‟.
The combination of studies related to aspirin for stopping
cancer makes the possibility of the
hybrid, powerful, gastrointestinal protective aspirin for
development as an anti-cancer drug intriguing.
http://digitaljournal.com/article/320418#ixzz1v8hwNjSv
http://digitaljournal.com/article/320418#ixzz1v8hFF3L0
No matter how easy cancer treatment may become, it is preferable to prevent cancer
Dual
Action
9. Rituxan - $3 billion
Avastin - $2.66 billion
Herceptin - $1.66 billion
Gleevec - $1.51 billion
Eloxatin - $1.2 billion
Alimta - $1.04 billion
Erbitux - $703.3 million
Velcade - $692.7 million
Xeloda - $647.6 million
Tarceva - $564.2 million
Dual
Action
None for prevention or control
10.
Proof of concept>>>>>>>>>>Completed
R&D>>>>>>>>>>>>>>>>>>Completed
Pilot scale >>>>>>>>>>>>> Completed
Lab. Testing>>>>>>>>>>>>>Completed
Animal Studies>>>>>>>>>>>Ongoing
Exit-1st- $100M
Manufacturing Process>Under development
GMP product >>>>>>>>>>>>Needed
Clinical-I
Bioequivalence>>>>>>>>>>> Needed
$1M
Invested
With
time
Exit-2nd- $250M
Dual
Action
$3M
Needed
12.
Our hybrid is designed to control inflammation
Water soluble
Synergistic effect
Potentiating each other
Potential to surpass existing aspirin brands
Dual
Action
No matter how easy cancer treatment may become, it is preferable to prevent cancer
14. Prostaglandin production is increased by VEGF-D+ which is produced by
metastatic cancer cells. Increased prostaglandin leads to dilation of
lymphatic vessels allowing cancer cells to spread. Aspirin prevents cancer
by inhibiting prostaglandin production, narrowing lymphatic vessels,
restricting spread of cancer.
Dual
Action
No matter how easy cancer treatment may become, it is preferable to prevent cancer
17. Facts
Nanocarriers serve as ideal delivery solutions for combination
therapy which is required for effectively treating MDR cancer.
The benefits of nanocarriers include,
(1) they can be engineered to achieve multiple effects using one
system; (2) nanocarriers improve the therapeutic index of drugs
and can alter the pharmacokinetic profile of agents; (3) they
preferentially accumulate in the tumor environment thanks to
the EPR effect and their capacity to be conjugated to targeting
moieties; and (4) nanocarriers avoid drug efflux by preferentially
localizing agents in the peri-nuclear region of a cell, away from
membrane localized efflux pumps.
Dual
Action
18. No matter how easy cancer treatment may
become, it is preferable to prevent cancer
Dual
Action
19. Available Brands
Currently, intravenous aspirin is not approved for use in the
United States. The poor solubility of aspirin in water and its
rapid hydrolysis in the plasma to salicylic acid and acetic
acid have limited its intravenous use.
Attempts have been made in the past to produce an aspirin
product having an acceptable solubility, but none have
proven to be totally satisfactory.
For example, the introduction of Bayer aspirin, as well as
Disprin (distributed in the United Kingdom), into water
results in the formation of a cloudy suspension indicative of
incomplete dissolution in water. Aspro Clear (distributed in
Australia and New Zealand and marketed throughout
Europe) imparts a non-cloudy, snow globe effect in water
for more than three minutes after the tablets have
effervesced.
Dual
Action Our Hybrid is unique and works much better and faster
